Study | Author | Update year | Trial Phase | Capecitabine arm | Control arm | N (Capecitabine/ Control) | TNBC, N (X/Control) | Median follow-up (month) | Design | Setting |
---|---|---|---|---|---|---|---|---|---|---|
FinXX Trial | Joensuu | 2017 | III | DX + CEX | D + CEF | 751/744 | 93/109 | 123.6 | Addition | Adjuvant |
GEICAM/2003–10 | MartÃn | 2015 | III | ED-X | EC-D | 715/669 | 95/71 | 79.2 | Replace | Adjuvant |
GAIN | V. Mo | 2017 | III | EC-PX | EPC | 1511/1512 | 213/208 | 74 | Replace | Adjuvant |
US ncology 01062 | O’Shaughnessy | 2015 | III | AC-DX | AC-D | 1307/1304 | 396/384 | 60 | Addition | Adjuvant |
CREATE-X | Masuda | 2017 | III | X | None | 443/444 | 139/147 | 43.2 | Addition | Adjuvant |
CIBOMA 2004/01 | Lluch | 2019 | III | ED-X | EC-D | 448/428 | 448/428 | 87.6 | Addition | Neo/Adjuvant |
Gepar TRIO | Minckwitz | 2013 | III | DAC-NX | DAC-DAC | 301/321 | NA | 62 | Replace | Neoadjuvant |
CBCSG-010 | Li | 2019 | III | DX-XEC | D-FEC | 297/288 | 297/288 | 67 | Addition | Adjuvant |
CALGB49907 | Muss | 2019 | III | X | CMF/AC | 307/326 | 76/78 | 136.8 | Replace | Adjuvant |